149 related articles for article (PubMed ID: 35884480)
1. Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide.
Skubitz KM; Domingo-Musibay E; Lindgren BR; Cheng EY
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884480
[TBL] [Abstract][Full Text] [Related]
2. Prospective Trial of Monocyte Count as a Biomarker of Hand-Foot Syndrome Among Patients With Soft Tissue Sarcomas Treated With Pegylated Liposomal Doxorubicin and Ifosfamide.
Skubitz KM; Lindgren BR; Domingo-Musibay E; Cheng EY
Cureus; 2022 Apr; 14(4):e24498. PubMed ID: 35651410
[TBL] [Abstract][Full Text] [Related]
3. High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma.
Strong EA; Park SH; Ethun CG; Chow B; King D; Bedi M; Charlson J; Mogal H; Tsai S; Christians K; Tran TB; Poultsides G; Grignol V; Howard JH; Tseng J; Roggin KK; Chouliaras K; Votanopoulos K; Cullinan D; Fields RC; Gamblin TC; Cardona K; Clarke CN
Surgery; 2020 Oct; 168(4):760-767. PubMed ID: 32736869
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.
Soyano AE; Dholaria B; Marin-Acevedo JA; Diehl N; Hodge D; Luo Y; Manochakian R; Chumsri S; Adjei A; Knutson KL; Lou Y
J Immunother Cancer; 2018 Nov; 6(1):129. PubMed ID: 30470260
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
[TBL] [Abstract][Full Text] [Related]
6. Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial.
De Sanctis R; Bertuzzi A; Basso U; Comandone A; Marchetti S; Marrari A; Colombo P; Lutman RF; Giordano L; Santoro A
Anticancer Res; 2015 Jan; 35(1):543-7. PubMed ID: 25550600
[TBL] [Abstract][Full Text] [Related]
7. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
9. Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304).
Tanaka K; Mizusawa J; Fukuda H; Araki N; Chuman H; Takahashi M; Ozaki T; Hiruma T; Tsuchiya H; Morioka H; Hatano H; Iwamoto Y
Jpn J Clin Oncol; 2015 Jun; 45(6):555-61. PubMed ID: 25838293
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.
Ho CL; Lu CS; Chen JH; Chen YG; Huang TC; Wu YY
Medicine (Baltimore); 2015 Jun; 94(24):e993. PubMed ID: 26091479
[TBL] [Abstract][Full Text] [Related]
12. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer.
Kwon YS; Han CS; Yu JW; Kim S; Modi P; Davis R; Park JH; Lee P; Ha YS; Kim WJ; Kim IY
Clin Genitourin Cancer; 2016 Feb; 14(1):e1-8. PubMed ID: 26341038
[TBL] [Abstract][Full Text] [Related]
14. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.
Judson I; Radford JA; Harris M; Blay JY; van Hoesel Q; le Cesne A; van Oosterom AT; Clemons MJ; Kamby C; Hermans C; Whittaker J; Donato di Paola E; Verweij J; Nielsen S
Eur J Cancer; 2001 May; 37(7):870-7. PubMed ID: 11313175
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas.
Viñal D; Martinez D; Garcia-Cuesta JA; Gutierrez-Sainz L; Martinez-Recio S; Villamayor J; Martinez-Marin V; Gallego A; Ortiz-Cruz E; Mendiola M; Pozo-Kreilinger JJ; Berjon A; Belinchon B; Bernabeu D; Espinosa E; Feliu J; Redondo A
Clin Transl Oncol; 2020 Oct; 22(10):1849-1856. PubMed ID: 32125644
[TBL] [Abstract][Full Text] [Related]
16. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
19. Preoperative lymphocyte count in relation to sarcoma prognosis.
Teck Seo S; Singh VA; Yasin NF
J Orthop Surg (Hong Kong); 2019; 27(2):2309499019854957. PubMed ID: 31221016
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children.
Womer RB; Daller RT; Fenton JG; Miser JS
Eur J Cancer; 2000 Jan; 36(1):87-94. PubMed ID: 10741300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
